Abstract
Purpose
An increasing body of evidence suggests gender differences in the presentation and prognosis of bladder cancer. We aimed to assess the impact of gender on outcomes in patients with primary T1 high-grade (HG) urothelial carcinoma of the bladder (UCB).
Methods
We retrospectively analysed the data from 916 patients with primary T1HG UCB from 7 tertiary care centres. Patients were treated with transurethral resection of the bladder with or without intravesical instillation therapy (IVT). Univariable and multivariable Cox regression analyses assessed the effect of gender on outcomes.
Results
Within a median follow-up of 42.8 months, 365 (39.8 %) patients experienced disease recurrence, 104 (11.4 %) progression, 59 (6.4 %) cancer-specific mortality and 190 (20.7 %) mortality of any cause. Overall, 634 (69.2 %) patients received IVT of which 234 (25.5 %) received BCG therapy. Female gender (n = 190, 20.7 %) was associated with higher risk of disease recurrence (HR:1.359;1.071–1.724, p = 0.012) in all patients and in a subgroup of patients treated with BCG therapy (HR:1.717;1.101–2.677, p = 0.017). There was no difference between genders with regard to disease progression, cancer-specific mortality and any-cause mortality. In multivariable analyses that adjusted for the effects of concomitant carcinoma in situ (CIS), tumour size, number of tumours, and IVT, gender remained an independent predictor for disease recurrence (p = 0.026) when analysed in all patients, but not in the subgroup of BCG treated patients (p = 0.093).
Conclusions
In patients with T1HG UCB, female gender is associated with higher risk of disease recurrence, but not with disease progression. This gender disparity may be due to differences in care and/or biology of UCB.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer JClin 62:10–29
Babjuk M, Oosterlinck W, Sylvester R et al (2011) European Association of Urology (EAU). EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008
Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182:2195–2203
Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 49:466–475
Fajkovic H, Halpern JA, Cha EK et al (2011) Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 29(4):457–463
NCCN clinical practice guidelines in oncology: bladder cancer 2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Rink M, Fajkovic H, Cha EK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855
Jeldres C, Isbarn H, Capitanio U et al (2009) Gender is an important predictor of cancer-specific survival in patients with urothelial carcinoma after radical cystectomy (abstract #1761). J Urol 181:635
Datta GD, Neville B, Datta NS, Earle C (2006) Gender disparities in bladder cancer survival: an assessment of sociodemographic factors. AACR Meet Abstract 2006:B38
Tilki D, Reich O, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 183:1757–1763
Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol 184:888–894
Tilki D, Svatek RS, Karakiewicz PI et al (2010) Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 183:87–93
Zhuang YH, Blauer M, Tammela T et al (1997) Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 30:556–562
Boorjian S, Ugras S, Mongan NP et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64:383–388
Shen SS, Smith CL, Hsieh JT et al (2006) Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 106:2610–2616
Saez S, Martin PM (1981) Evidence of estrogen receptors in the trigonearea of human urinary bladder. J Steroid Biochem 15:317–320
McGrath M, Michaud DS, De Vivo I (2006) Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 163:236–244
Boorjian SA, Zhu F, Herr HW (2010) The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106(3):357–361
Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA (2000) Gender differences in stage distribution of bladder cancer. Urology 55:368–371
Micheli A, Mariotto A, Rossi AG et al (1998) The prognostic role of gender in survival of adult cancer patients. Eur J Cancer 34:2271–2278
Kiemeney LALM, Coebergh JWW, Koper NP et al (1994) Bladder cancer incidence and survival in the south-eastern part of the Netherlands, 1975–1989. Eur J Cancer 30A:1134–1137
Fleshner NE, Herr HW, Stewart AK et al (1996) For the American College of Surgeons on Cancer and the American Cancer Society: the National Data Base Report on bladder carcinoma. Cancer 78:1505–1509
Mungan NA, Aben KK, Schoenberg MP et al (2000) Gender differences in stage-adjusted bladder cancer survival. Urology 55:876–880
Puente D, Malats N, Cecchini L et al (2003) Gender-related divergence in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 43:53–62
Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, (2012) Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 62(1):118–125. Epub 2011 Oct 25
Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10):1402–1412
Rink M, Robinson BD, Green DA et al (2012) Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol 188(2):398–404
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Luis A. Kluth and Harun Fajkovic have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kluth, L.A., Fajkovic, H., Xylinas, E. et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31, 1029–1036 (2013). https://doi.org/10.1007/s00345-012-0996-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-012-0996-9